| First Author | Cho E | Year | 2023 |
| Journal | Biomed Pharmacother | Volume | 161 |
| Pages | 114511 | PubMed ID | 36913892 |
| Mgi Jnum | J:334492 | Mgi Id | MGI:7450562 |
| Doi | 10.1016/j.biopha.2023.114511 | Citation | Cho E, et al. (2023) Phyllodulcin improves hippocampal long-term potentiation in 5XFAD mice. Biomed Pharmacother 161:114511 |
| abstractText | Alzheimer's disease (AD) is a well-known neurodegenerative brain disease, and no curative treatment has yet been developed. The main symptoms include various brain lesions, caused by amyloid beta (Abeta) aggregation, and cognitive decline. Therefore, it is believed that substances that control Abeta will inhibit the onset of Alzheimer's disease and slow its progression. In this study, the effect of phyllodulcin, a major component of hydrangea, on Abeta aggregation and brain pathology in an animal model of AD was studied. Phyllodulcin inhibited the aggregation of Abeta and decomposed the pre-aggregated Abeta in a concentration-dependent manner. In addition, it inhibited the cytotoxicity of Abeta aggregates. Oral administration of phyllodulcin improved Abeta-induced memory impairments in normal mice, reduced Abeta deposition in the hippocampus, inhibited the activation of microglia and astrocytes, and improved synaptic plasticity in 5XFAD mice. These results suggest that phyllodulcin may be a candidate for the treatment of AD. |
